MedTechIQ_3Helix InSight Engine-Beta
Preview
Open in TheBrain
Triple Helix Discovery Engine
*Driving Forces: Market Research, Intelligence, Analysis, Datapoints, Databases & Trends
*Driving Forces: BioPharmaceuticals _ Biotechnology, Genomics, Genetics, Bioinformatics, Biomanufacturing & Personalized Medicine
*Biotechnology: Key Issues
*Key Terms: Biotechnology
Mitochondrial Disease
Parents
*Key Terms: Biotechnology
2023: DOD_CDMRP_FY23 Peer Reviewed Medical Research Program (PRMRP)
BioTechnology
Children
*Stealth BioTherapeutics Corp, a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of therapies for diseases involving mitochondrial dysfunction.
2020: Mitochondrial Transplantation to Treat Ischemia-Reperfusion Injury: Interview with Dr. Alexander Schueller, CEO of cellvie
2021: Off the beaten path(way): Spatiotemporal investigation of protein assemblies controlling mitochondrial metabolism_ RePORT 〉 RePORTER
2021: To date, the company has discovered more than 100 mitochondrial derived peptides and invented over 1,000 analogs.
2025: NHLBI_NOSI_Promoting Fundamental Research on Mitochondrial Involvement in Lung Diseases and Sleep Disorders
A clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies for treating heart failure with reduced ejection fraction (HFrEF), heart failure with preserved ejection fraction (HFpEF) of specific etiology, as well as neurological and metabolic disorders involving mitochondrial dysfunction.
CohBar (NASDAQ: CWBR) is a clinical stage biotechnology company focused on the research and development of mitochondria based therapeutics, an emerging class of drugs for the treatment of chronic and age-related diseases.
Developing therapeutics that promote mitochondrial biogenesis and function through a novel mechanism of action discovered by the company
Development-stage biotechnology company focused on mitochondria rejuvenation to improve fertility
Discovery and development of drugs for mitochondrial diseases
Diseases of aging in the areas of metabolic and mitochondrial disorders
Focused on harnessing the power of mitochondria to fight disease
Microfluidic Device for Mitochondrial Membrane Potential Measurement:UCSB
Mission Therapeutics is an early-stage drug development company targeting the ubiquitin pathway for the treatment of kidney disease, neurodegenerative disease, rare mitochondrial diseases and fibrosis
Mitochondria based therapeutics originate from the discovery by CohBar’s founders of a novel group of naturally occurring peptide sequences within the mitochondrial genome, some of which have been shown to have the potential to regulate key processes in multiple systems and organs in the body.
MitoSense, Inc.
Other promising approaches also under investigation include novel mitochondrial targeted anti-oxidants as well as therapeutics affecting the epigenetic response to stress.
Razor focused on rare mitochondrial DNA depletion disorders
Small molecule company focused on mitochondrial disease Friedreich’s ataxia
The treatment is believed to reduce cellular oxygen consumption by reversibly inhibiting the mitochondrial enzyme cytochrome oxidase and by acting as an electron acceptor alternative for oxygen.